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ABSTRACT. Experimental evidence indicates that 
estrogen exerts neuroprotective effects. Accord-
ing to the fact that Alzheimer’s disease (AD) is 
more common in post-menopausal women, estro-
gen treatment has been proposed. However, the 
beneficial effect of estrogen or selective estrogen 
receptor modulators (SERMs) in preventing or 
treating AD is a controversial issue, which will be 
summarized in this review. Recently, a novel gene, 
named selective AD indicator-1 (seladin-1), has 
been isolated and found to be down-regulated 
in brain regions affected by AD. Seladin-1, which 
is considered the human homolog of the plant 
protein DIMINUTO/DWARF1, confers protection 
against β-amyloid-mediated toxicity and from 
oxidative stress and is an effective inhibitor of 
caspase 3 activity, a key mediator of apoptosis. 
This review will present the up-to-date findings 
regarding seladin-1 and DIMINUTO/DWARF1. In 
addition, the possibility that seladin-1 may be a 
downstream effector of estrogen receptor activa-
tion in the brain, based on our recent experimen-
tal findings using a human fetal neuronal model, 
will be addressed.
(J. Endocrinol. Invest. 28: 285-293, 2005)
©2005, Editrice Kurtis
INTRODUCTION
Epidemiological data, together with experimental 
and clinical evidence, appear to support a neuro-
protective role of estrogen and hormonal therapy 
in Alzheimer’s disease (AD), the most prevalent 
neurodegenerative disorder in the elderly, has been 
suggested. However, there is no general consensus 
on this point, which will be briefly summarized in 
this review. As a matter of fact, this story is far from 
being concluded. A debated question concerns 
the factors which act as downstream mediators of 
estrogen receptor activation in the brain. The re-
cent identification of the selective AD indicator-1 
(seladin-1) gene and the finding that it protects the 
brain from toxic insults led us to hypothesize that 
this gene might represent the link between estro-
gen and neuroprotection. Seladin-1 shares a high 
degree of sequence homology and some biological 
functions with a previously identified plant enzyme, 
named DIMINUTO/DWARF1, which is involved in 
the biosynthesis of brassinosteroids (BRs), an impor-
tant class of plant hormones. This review will present 
the current knowledge on seladin-1 and on its plant 
homolog DIMINUTO/DWARF1. Furthermore, the 
possible role of seladin-1 as a target of estrogen 
receptor activation in the brain, based on our recent 
experimental findings, will be addressed.
ESTROGEN/SERMS AND NEUROPROTECTION: EX-
PERIMENTAL AND CLINICAL EVIDENCE
This topic has been extensively reviewed by many 
authors and the current experimental and clinical 
knowledge will be briefly reported in this review. It 
is well known, based on in vitro evidence, that estro-
gen exerts neurotrophic and neuroprotective effects 
by stimulating the expression of neurotrophins and 
cell-survival factors, enhancing synaptic plasticity 
and acting as an antioxidant factor (1-3). Besides the 
hypothalamus, which is the traditional site of estro-
gen action in the brain, both the estrogen receptor 
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α (ERα) and β (ERβ) have been found, for instance, 
in the neocortex and in the hippocampus, two brain 
areas highly involved in AD (2). AD, which is the most 
prevalent form of late-life mental failure in humans, is 
characterized by a progressive impairment of cogni-
tive functions, such as memory and language. The 
histopathological hallmark of AD is represented by 
the accumulation of extracellular β-amyloid plaques 
and intracellular neurofibrillary tangles, which are 
responsible for a complex inflammatory response 
leading to neuronal degeneration and cell death (4). 
Unfortunately, there is still no reliable way of predict-
ing the onset of the disease and of effectively curing 
it. The fact that experimental evidence advocates a 
favorable estrogen effect in neurons, together with 
the knowledge that AD is more common in women 
and decreased estrogen levels after menopause are 
a risk factor for the disease (5), led to the sugges-
tion that estrogen therapy might be beneficial. To 
date, despite the lack of general consensus, several 
studies have indicated that estrogen treatment may 
decrease the risk or delay the onset of AD in post-
menopausal women (6). Conversely, the recent data 
from the Women’s Health Initiative Memory Study 
trial and from the trial of estrogen treatment for AD 
showed that hormone replacement therapy (HRT) 
has no benefit. However, it has to be remembered 
that different factors may determine the efficacy of 
estrogen or HRT, such as age, menopausal status, 
pre-existing risk factors (i.e. smoking, apolipoprotein 
E genotype) (7-9). In particular, there seems to be a 
critical time for estrogen treatment. In fact, early and 
prolonged therapy has been found to produce the 
maximum benefit in terms of reduced risk for AD (10, 
11). In addition, estrogen therapy is not the same as 
HRT, and the type of progestogen used determines 
the outcome of the therapeutic intervention (9). 
A debated question is whether the protection 
conferred by classical nuclear estrogen receptors 
is mediated by the α or the β subtype or by both. 
Although the results from ERα knockout (ERKO) and 
ERβ knockout (βERKO) mice are somewhat contro-
versial, it is worth noting that, whereas 17βestradiol 
(17βE2) exerted a protective effect in the brain of 
ovariectomized βERKO mice, it did not in ERKO 
mice, thus suggesting a critical role for ERα in neuro-
protection (12). Furthermore, it is worth mentioning 
that decreased expression of ERα in hippocampal 
neurons of AD patients has been observed (13). How-
ever, a possible role for ERβ in neuroprotection has 
been postulated, based on the evidence that βERKO 
mice undergo increased neuronal loss throughout 
life compared with wild-type controls (14). In addi-
tion to classical nuclear ERs, more recent findings 
suggest that the brain contains a plethora of ERs. 
For instance, a third member of the ER family, ERγ, 
has been identified (15). Furthermore, a variety of 
nuclear, cytoplasmic and plasma membrane ERs has 
been described in the brain, including for instance G 
protein-coupled receptors, a novel membrane-asso-
ciated ER-X and a truncated ERα variant (16).
Less is known about the neuroprotective role of the se-
lective estrogen receptor modulators (SERMs). None-
theless, a neuroprotective effect of tamoxifen (TMX) 
and raloxifene (Ral) has been observed (17), and a 
beneficial role of TMX and Ral against β-amyloid tox-
icity has been demonstrated in rat neurons (18, 19). In 
addition to neuroprotective effects, there is increasing 
evidence that SERMs may also be neurotrophic, by in-
creasing for instance synaptic density and stimulating 
neurite outgrowth (17). Data regarding the clinical use 
of SERMs in AD are very limited, so far. However, from 
the Multiple Outcomes of Raloxifene Evaluation trial, 
in which more than 7000 women with osteoporosis 
were assigned to receive Ral (60 or 120 mg) or place-
bo daily for three years, a trend toward less cognitive 
decline in the Ral group on tests of verbal memory 
and attention was observed (20).
In summary, the basic science strongly supports a 
neuroprotective role of estrogen/SERMs. Although 
currently there is no clear cut evidence that these 
molecules can decrease the risk or ameliorate the 
clinical course of AD, it is conceivable that there 
might be a proper space for a hormonal-based in-
tervention in this disease.
THE IDENTIFICATION AND CHARACTERIZATION 
OF SELADIN-1
In 2000, Greeve et al. (21) used a differential mRNA 
display approach to identify genes that were differen-
tially expressed in selective vulnerable brain regions 
in AD. In fact, although intracellular neurofibrillary 
tangles and extracellular and perivascular deposits of 
β-amyloid, the histopathological hallmarks of AD, are 
evenly distributed throughout the brain, substantial 
loss of neurons and synapses occurs only in selective 
brain regions, such as the hippocampus, the amy-
gdala, the inferior temporal cortex and the enthorhi-
nal cortex (4). Conversely, neurons populating other 
brain regions, such as the frontal, the parietal and 
the occipital cortex, are protected from degenera-
tion. Among the >30 genes differentially expressed 
in AD vulnerable brain regions vs unaffected areas, 
Greeve et al. identified a novel cDNA with a markedly 
reduced expression in the inferior temporal cortex of 
AD patients compared to the frontal cortex, obtained 
shortly post mortem. Conversely, this cDNA was 
evenly expressed in the brain of unaffected individu-
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als. This gene was named seladin-1 from selective 
Alzheimer’s disease Indicator-1 and its full-length 
cDNA was cloned from a human brain cDNA library 
(GenBank accession number AF261758). The seladin-
1 gene spans 46.4 kb, maps to chromosome 1p31.1-
p33, and comprises nine exons and eight introns; it 
encodes an open reading frame of 516 amino acid 
residues. To localize the cellular distribution of sela-
din-1, human H4 neuroglioma cells were transfected 
with a seladin-1-green fluorescent protein (GFP) 
fusion construct. Seladin-1 appeared to be mainly 
located in the endoplasmic reticulum and, although 
to a lesser extent, in the Golgi apparatus. 
With regard to its biological effects, seladin-1 was 
found to confer resistance against β-amyloid and 
oxidative stress-induced apoptosis and to effectively 
inhibit the activation of caspase 3, a key mediator 
of the apoptotic process. Interestingly, in PC12 cells 
that were selected for resistance against β-amyloid 
toxicity, the level of expression of seladin-1 was re-
markably high. A subsequent study demonstrated 
that the down-regulation of seladin-1 expression 
in vulnerable AD brain areas is paralleled by an in-
crease in the amount of hyperhosphorylated tau, a 
protein component of neurofibrillary tangles (22).
Apart from the brain, seladin-1 mRNA has also been 
detected in many different human organs and the 
highest levels of expression have been found in the 
adrenal gland, the liver, the lung and the prostate. 
In the adrenal cortex, seladin-1 expression is stimu-
lated by ACTH via the cAMP-dependent pathway: 
accordingly, in cortisol-secreting adenomas seladin-
1 appeared to be overexpressed compared to the 
atrophic adjacent adrenal tissue (23). In a subsequent 
study, we observed that the expression level of sela-
din-1 in adrenal carcinomas is significantly lower than 
in the normal adrenal and in adrenal benign corti-
sol- or aldosterone-secreting adenomas (24). These 
results are in agreement with the very recent finding 
that seladin-1, upon binding to p53, may also have a 
tumor suppressor role, involved in cellular response to 
Ras/p53-mediated oncogenic signaling (25).
An important step forward in discovering the biolog-
ical properties of seladin-1 was represented by the 
demonstration that this protein also has a specific 
enzymatic activity, which was found to be markedly 
reduced in desmosterolosis, a rare autosomal reces-
sive disorder characterized by multiple congenital 
anomalies (26). In fact, patients with desmostero-
losis have elevated plasma levels of the cholesterol 
precursor desmosterol (Fig. 1), and this abnormality 
suggested a deficiency of the enzyme 3β-hydroxys-
terol Δ24-reductase (DHCR24), which catalyzes the 
reduction of the Δ24 double bond in desmosterol 
to produce cholesterol. Waterham et al. (27) were 
able to identify the human DHCR24 cDNA, which 
appeared identical to seladin-1. DHCR24 activity 
was confirmed in vitro by enzymatic assay following 
heterologous expression of the DHCR24 cDNA in 
Saccharomyces cerevisiae. Conversely, in constructs 
containing mutant DHCR24 alleles from patients 
with desmosterolosis the conversion from desmos-
terol into cholesterol was nil or markedly reduced. 
Desmosterolosis belongs to a group of several inher-
ited disorders, linked to enzyme defects in the cho-
lesterol biosynthetic pathway at the post-squalene 
level, which have been described in recent years 
(Fig. 1) (28). These genetic diseases are character-
ized by major developmental malformations and in 
most cases determine severe neuro-psycological 
alterations, suggesting an important role for choles-
terol in brain homeostasis. The role of cholesterol in 
facilitating the onset and progression of AD is a de-
bated and unsolved question. In fact, on one hand 
cholesterol may be viewed as a toxic factor. Elevated 
cholesterol levels increase β-amyloid formation in in 
vitro systems and in most animal models of AD (29, 
30). The identification of the ε4 allelic variant of the 
apolipoprotein E as a major genetic risk factor for 
AD is also consistent with a role for cholesterol in the 
pathogenesis of this disease. Accordingly, epidemi-
ological studies suggest that statin therapy may pro-
vide protection against AD (31), although the clinical 
benefit of statins might also be due to their choles-
terol-independent effects on cerebral circulation and 
inflammation (31). On the other hand, it has to be 
considered that the central nervous system (CNS) is a 
very unique structure with regard to cholesterol me-
tabolism: in fact, although the CNS accounts for only 
2% of the entire body mass, it contains about 25% 
of the total amount of unesterified cholesterol in the 
entire body. In addition, most of the CNS cholesterol 
is produced via local de novo synthesis. Keeping this 
in mind, it is not surprising that several studies point-
ed out the fact that the intracellular content of cho-
lesterol, particularly the amount contained in the cell 
membrane, should be addressed much more than its 
plasma levels (29). In this new scenario, an appropri-
ate amount of membrane cholesterol would create 
a barrier against toxic insults, whereas a cholesterol-
depleted membrane would ease the interaction with 
toxic factors such as β-amyloid, which may generate 
for instance an anomalous number of calcium chan-
nels leading to the accumulation of toxic levels of 
calcium (32). Interestingly, in AD patients impaired 
or lack of 3-hydroxy-3-methylglutaryl-CoA reduct-
ase activity in the affected brain regions has been 
reported. Undoubtedly, the reduced expression of 
seladin-1 in AD vulnerable regions is in keeping with 
the “membrane integrity” theory.  
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Recently, mice with a targeted disruption of the DH-
CR24 gene have been generated (33). As expected, 
plasma and tissues of DHCR24-/- mice contained virtu-
ally no cholesterol, whereas desmosterol accumulation 
was observed. These animals were around 25% smaller 
in size than DHCR24+/+ and DHCR24+/- littermates 
at birth and survived to adulthood, although with poor 
growth features. Histologically, all organs showed a 
normal structure with the exception of the testes, in 
which germ cell degeneration was observed. Both 
males and females were infertile. Admittedly, the rela-
tively mild phenotype of DHCR24-/- is in overt contrast 
with the severe abnormalities observed in patients 
with desmosterolosis. It has been speculated that this 
discrepancy may be due to the fact that maternal cho-
lesterol is not available during human embryogenesis, 
as it is in mice. Alternatively, desmosterol, which has 
been shown to replace cholesterol in mouse fibroblasts 
without toxic effects (34), might act as a “cholesterol-
mimetic” steroid in DHCR24-/- animals.
Another interesting aspect related to the identifica-
tion of the seladin-1 gene is represented by the high 
degree of sequence homology and by the similar 
enzymatic activity shared with the plant enzyme 
DIMINUTO-DWARF1, described in Arabidopsis 
thaliana.
THE PLANT DIMINUTO/DWARF1 GENE
DIMINUTO/DWARF1 is a gene encoding for an enzyme 
involved in the biosynthetic  pathway of the most active 
BR, brassinolide (35) (Fig. 2). BRs are a class of sterol plant 
hormones that can be considered as the counterpart of 
animal steroid hormones. They have been shown to 
regulate gene expression, stimulate cell division and 
differentiation, and modulate reproductive biology (36). 
BRs also mediate growth response unique to plants, in-
cluding the promotion of cell elongation in the presence 
of a complex cell wall and the multiple developmental 
responses to darkness and light.
Isoprenoid biosynthetic pathway
Squalene synthase
Squalene epoxidase
2.3-oxidosqualene sterol cyclase
DHCR24SC14DM
squalene
HO
4, 4, 14α-trimethylcholesta-8 (9), 24-
dien-3β-ol (lanosterol)
DHCR14
4, 4 -dimethylcholesta-8 (9), 24-trien-3β-ol
HO DHCR14
DHCR14
DHCR14
DHCR14
DHCR14
SC4DM
4, 4 -dimethylcholesta-8 (9), 24-dien-3β-ol
HO
cholesta-8(9), 24-dien-3β-ol
(zymosterol)
HO
cholesta-7, 24-dien-3β-ol
HO
cholesta-5, 7, 24-dien-3β-ol
HO
cholesta-5, 24-dien-3β-ol
(desmosterol)
HO
S∆5DS
DHCR7
Conradi-Hunermann
syndrome
Desmosterolosis
S∆8-7I
DHCR24 DHCR7
SC14DM
4, 4 14α-trimethylcholesta-8 (9)-en-3β-ol
HO
4, 4 -dimethylcholesta-8 (9), 14-dien-3β-ol
HO
4, 4-dimethylcholesta-8(9), 24-en-3β-ol
HO
cholesta-8 (9)-en-3β-ol
HO
cholesta-7-en-3β-ol
(lathosterol)
HO
cholesta-5, 7-dien-3β-ol
(7-dehydrocholesterol)
HO
S∆8-7I
Greenberg skeletal
displasia
Smith-Lemli-Opiz
syndrome
SC4DM
DHCR14
S∆5DS
CHILD
syndrome
Lathosterolosis
Fig. 1 - Cholesterol biosynthesis from squalene. Deficiencies of the circled enzymes are responsible for different inherited disorders 
of cholesterol biosynthesis. DHCR24: 3β-hydroxysterol Δ24-reductase (Desmosterolosis); SC14DM: 3β-hydroxysterol C14 demethylase; 
DHCR14: 3β-hydroxysterol Δ14-reductase (Greenberg skeletal dysplasia); SC4DM: 3β-hydroxysterol C4 demethylase complex (including 
a 3β-hydroxysteroid dehydrogenase defective in CHILD syndrome); SΔ8-7I, 3β-hydroxysterol Δ8-Δ7 isomerase (Conradi-Hunermann syn-
drome); SΔ5DS: 3β-hydroxysterol Δ5-desaturase (lathosterolosis); DHCR7: 3β-hydroxysterol Δ7-reductase (Smith-Lemli-Opiz syndrome). 
Modified from (28).
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The function of DIMINUTO/DWARF1 was identified 
analyzing the dim mutant of Arabidopsis thaliana, 
which shows a severe dwarf phenotype with re-
duced fertility (37). The mutant phenotype could be 
rescued by the addition of exogenous brassinolide 
or brassinolide precursors, indicating a role in BR 
biosynthesis. The specific enzymatic step in which 
DIMINUTO/DWARF1 is involved was elucidated by 
the analysis of endogenous sterols in the mutant. In 
fact, the dim mutant accumulates 24-methylencol-
hesterol and is deficient in campesterol, a key pre-
cursor of brassinolide. Feeding experiments with the 
deuterated precursor established that this protein 
catalyzes the isomerization of 24-methylencolhes-
terol to 24-methyldesmosterol and successively the 
reduction of the Δ24-25 double bond to yield campes-
terol. The same reactions result in the synthesis of 
sitosterol from isofucosterol. Transient expression of 
the fusion protein DIMINUTO/DWARF1 with GFP 
strongly suggests that DIMINUTO/DWARF1 is an in-
tegral membrane protein probably associated with 
the endoplasmic reticulum.
DIMINUTO/DWARF1 is therefore responsible for the 
synthesis of the main plant membrane sterol lipids 
sitosterol and campesterol, the latter being also 
the key precursor of the steroid-like hormones BRs. 
Sterols are used by many organisms both as modu-
lators of membrane elasticity and as precursors for 
the synthesis of steroid hormones. Animals mainly 
synthesize cholesterol, which serves as a precursor 
of steroid hormones after the cleavage of the alkyl 
side chain, and as a membrane sterol lipid. Plants 
use campesterol as a hormone precursor and both 
sitosterol and campesterol as membrane lipids. 
The plant protein DIMINUTO/DWARF1 and sela-
din-1 share a similar function as sterol biosynthetic 
6α-Hydroxy
castasterone
D
(P450 steroid hydroxylase)
D
6-Deoxo
castasterone
6-Deoxotyphasterol
3-Dehydro-6-deoxoteasterone
6-Deoxoteasterone
(P450 steroid hydroxylase)
CPD/CBB3/DWF3
6-Deoxoteasterone
DWF4 (P450 steroid hydroxylase)
Late C6-oxidation
Campestanol
3-Dehydrocampestanol
DET2 (steroid-5a-reductase),IK
3-Dehydro-∆4,5-campestanol
sax1?
24-Methylencholesterol
5-Dehydrolsterol
DWF7/STE1 (∆7-sterol desaturase)
Episterol
CycloartenolSqualene
Mevalonic acid
∆24, 25-Campestanol
DIM1/DWF1(FAD-dependent oxidase),LKb
Campestanol
DIM1/DWF1(FAD-dependent oxidase),LKb
Early C6-oxidation
6α-Hydroxy
campestanol
(P450 steroid hydroxylase)
6-Oxocampestanol
DWF4
Cathasterone
(P450 steroid hydroxylase)
CPD/CBB3/DWF3
Teasterone
3-Dehydroteasterone
Typhasterol
Castasterone
Brassinolide
Fig. 2 - Biosynthetic pathway of brassi-
nolide. The plant homolog of seladin-1, 
DIMINUTO/DWARF1(DIM1/DWF1) is cir-
cled. Modified from (35).
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enzymes. Unlike humans, the defect of this func-
tion does not influence plant embryogenesis, that 
seems to be influenced by upstream precursors 
of 24-methylencholesterol (24-methylenlophenol) 
(38). Moreover, the disruption of the DIMINUTO/
DWARF1 gene seems to expand the life span of 
the dim mutant and this phenomenon is probably 
associated to the reduced fertility of the plant (39). 
Interestingly, Arabidopsis with a mutation in one of 
the gene homologues of 3-hydroxy-3-methylglutar-
yl-CoA reductase (40), the first step in the isoprenoid 
biosynthesis, shows an early senescence indicating 
that the roles of plant sterols are probably more di-
versified and structure-dependent than in animals 
where cholesterol seems to perform multiple func-
tions. Nevertheless, unraveling the biochemistry 
and the biological functions of sterols in plants may 
represent a fundamental step in the comprehension 
of the involvement of this class of lipids in human 
physiology and pathology. What is noteworthy is 
that plant-derived sterols have been found in mam-
mal brain (41), opening a new window on their pos-
sible therapeutic use in human diseases. With regard 
to this point, the identification of the seladin-1 gene 
as the human homolog of the plant DIMINUTO/
DWARF1 gene and the discovery of its implication 
in AD, which represents a scientific and medical 
problem but also a profound social and economic 
burden, constitutes an important advancement in 
understanding the biology of neuronal cells.
SELADIN-1: A NEW EFFECTOR OF ER-MEDIATED 
NEUROPROTECTION?
Because of the parallelism between some of the 
biological properties of seladin-1 and the effects of 
estrogen and SERMs in neurons, we hypothesized 
that seladin-1 might be targeted as a downstream 
effector of the activation of estrogen receptors in 
the brain. As mentioned previously, there is ex-
perimental evidence that estrogen and SERMs may 
confer neuroprotection. However, in most of the 
studies which have been performed so far, animal 
models have been used. In other cases human cells, 
transformed or of neoplastic origin, have been used. 
We had the opportunity to study the neuroprotec-
tive effects of estrogen/SERMs using a unique 
human cell model. This model is represented by 
GnRH-secreting neuroblast long-term cell cultures 
from human fetal (8-12 weeks of gestational age) 
olfactory epithelium. These cells, named FNC, were 
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Fig. 3 - Effect of different concentrations of 17β estradiol (17βE2) 
(A), or raloxifene (B) on β-amyloid (10 and 100 nM) toxicity, as as-
sessed by MTS assay (Promega Corp., Madison, WI). *=p<0.05 vs 
untreated control cells.
Fig. 4 - TUNEL analysis of β-amyloid-in-
duced apoptosis. A) control FNC cells; 
B) cells exposed to 100 nM β-amyloid. The 
arrows indicate fragmented nuclei derived 
from clumps of cells; C) cells pretreated 
with 100 pM 17β estradiol (17βE2) before 
β-amyloid exposure (100 nM).
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established, cloned and propagated previously by 
Vannelli et al. (42) at the Department of Anatomy, 
Histology, and Forensic Medicine of the University 
of Florence. They showed unique features, because 
they stained positively for neuronal and olfactory 
markers, such as neuron specific-enolase and vi-
mentin, which target maturing olfactory receptor 
neurons, and neural cell adhesion molecule and ol-
factory marker protein, which appear at a relatively 
later stage during differentiation (42). FNC cells are 
electrically excitable and following exposure to a 
number of different aromatic chemicals showed a 
specific increase in intracellular cAMP, indicating 
some degree of functional maturity. Thus, FNC cells 
appear to originate from the stem cell compartment 
that generates mature olfactory receptor neurons. 
In addition, they express both ERα and ERβ (43). 
Therefore, they represented an appropriate, and 
most importantly human, in vitro model, that could 
be of help in providing further information on the 
role of estrogen in neurons, and in answering the 
question whether seladin-1 may be an effector of 
ERs activation.
We first evaluated the role of 17βE2 on FNC sur-
vival after β-amyloid exposure. We observed that, 
whereas in the absence of estrogen pre-incubation 
β-amyloid (10 and 100 nM for 18 h) significantly and 
dose-dependently reduced cell viability (Fig. 3A), the 
pre-treatment with 17βE2 (100 pM-100 nM for 72 h) 
effectively counteracted the effect of β-amyloid (44). 
Noticeably, this effect was independent of increased 
cell proliferation rate, which was not changed by 
exposure to estrogen for 72 h. Virtually superimpos-
able data were obtained using the SERM TMX (100 
pM-100 nM) (data not shown), whereas partially dif-
ferent results were observed using Ral. In fact, cell 
viability was preserved at low concentrations of Ral 
(100 pM and 1 nM). Conversely, 10 and 100 nM Ral 
did not protect against β-amyloid-induced toxicity 
(Fig. 3B). Similarly to estrogen, neither TMX nor Ral 
had any effect on cell proliferation rate. A protec-
tive effect of 17βE2 against oxidative stress (200 µM 
H2O2) was also observed: in fact, the negative effect 
of H2O2 on cell viability was prevented by pre-expo-
sure to 100 pM-100 nM 17βE2 (not shown).
Next, in order to determine whether the protective 
action of estrogen in FNC cells was associated to 
an effect on apotosis, the amount of apoptotic cells 
following β-amyloid exposure, in the absence or in 
the presence of 17βE2, was evaluated. TUNEL analy-
sis clearly revealed that the pro-apoptotic effect of 
100 nM β-amyloid was counteracted by estrogen 
(100 pM 17βE2) (Fig. 4). Similarly, the activation of 
caspase 3, a key mediator of apoptosis, which was 
induced by β-amyloid, was prevented by estrogen 
pre-treatment (Fig. 5). 
Finally, in order to answer the question whether 
estrogen and/or SERMs have an effect on seladin-1 
expression, we evaluated the amount of seladin-1 
mRNA in FNC cells, treated or not with 17βE2, TMX 
A B C
Fig 5 - Immunocytochemical detection of 
cleaved caspase 3. A) control FNC cells; 
B) immunostained cells, with a variable 
degree of positivity, after exposure to 
100 nM β-amyloid; C) cells pretreated 
with 100 pM 17β estradiol (17βE2) before 
β-amyloid exposure (100 nM).
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Fig. 6 - Amount of seladin-1 mRNA, assessed by real-time RT-PCR, 
in untreated control FNC cells (C), in cells treated with 1 nM 17β 
estradiol (17βE2) or tamoxifen (TMX), with raloxifene (Ral) (1-100 
nM), with 10 nM propylpyzazole (PPT) or diarylpropionitrile (DPN). 
*=p<0.05 vs control cells (C) value (112±2.26 fg/µg total RNA, 
mean±SE), considered as 100%.
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or Ral, by quantitative real-time RT-PCR based on 
TaqMan technologies. We found that FNC cells con-
stitutively express seladin-1 (112±2.26 fg/µg total 
RNA, mean+SE) (Fig. 6). Noticeably, 17βE2 (10 pM-
100 nM) significantly increased the amount of sela-
din-1 mRNA. 1 nM TMX or Ral determined a similar 
increase of seladin-1 mRNA, compared to an equal 
concentration of 17βE2. However, higher concentra-
tions of Ral (10-100 nM) determined a marked reduc-
tion of seladin-1 expression, in keeping with the lack 
of a neuroprotective effect. The effect of a selective 
ERα [propylpyrazole-triol, (PPT)] or a selective ERβ 
[diarylpropionitrile (DPN)] agonist was also tested. 
We found that PPT determined a significant increase 
in the amount of seladin-1 mRNA at a concentration 
(10 nM) which has been reported to induce evident 
transcriptional activity (45), whereas DPN produced 
a weaker effect, thus indicating a predominant role 
of ERα in mediating the stimulatory effect of estro-
gen on seladin-1 expression. 
CONCLUSIONS
Our original results strongly support a role for ERs-
mediated neuroprotection. A rather unique feature 
of our study is represented by the fact that the ex-
perimental data have been generated using human 
neuroblasts. In addition to 17βE2, we also provided 
evidence that the SERMs TMX and Ral may act as es-
trogen agonists in the brain and highlight the possi-
bility that SERMs may be beneficial in the treatment 
of neurodegenerative disorders such as AD. 
Our study also addressed for the first time the role of 
seladin-1 in mediating the effects of ERs activation in 
the brain. In the in vitro model we used we demon-
strated that estrogen, TMX and Ral (the latter only at 
low concentrations) increase the expression level of 
seladin-1. Although a conclusive statement on the 
role of seladin-1 as an effector of the neuroprotective 
role of estrogen cannot be advocated at present, our 
findings suggest that this might be a likely hypothesis. 
In fact, the marked parallelism between the concen-
trations of Ral which provide neuroprotection and the 
concentrations which stimulate seladin-1 expression 
appears to be strongly in favor of this hypothesis. 
The fact that estrogen is able to stimulate seladin-1 
expression on one hand and to prevent β-amyloid-in-
duced activation of caspase 3 on the other hand, fur-
ther supports a role for seladin-1 as a transcriptional 
target of estrogen. Nevertheless, additional studies, 
specifically designed to study for instance the effect of 
estrogen/SERMs upon silencing seladin-1 expression, 
will be needed to further confirm the involvement of 
this gene in hormonal-mediated neuroprotection. 
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